Robert Ephron's most recent trade in Synaptogenix Inc was a trade of 800 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Synaptogenix Inc | Robert Ephron | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2026 | 800 | 800 | - | - | Stock Option (Right to Buy) | |
| Synaptogenix Inc | Robert Ephron | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Oct 2025 | 7,500 | 7,500 | - | 0 | Common Stock, par value $0.0001 per share | |
| Synaptogenix Inc | Robert Ephron | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.23 per share. | 17 Oct 2025 | 3,000 | 4,500 | - | 7.2 | 21,690 | Common Stock, par value $0.0001 per share |